Journal of Psychoactive Drugs Publishes Peer Reviewed Ketamine Research Foundation Study on the Duration of the Presence of Ketamine in Breast Milk
Retrieved on:
Monday, August 8, 2022
Research, Philanthropy, Pharmaceutical, Consumer, Mental Health, Foundation, Parenting, Clinical Trials, Science, Baby, Maternity, Women, FDA, Health, Woman, Psychoactive drug, Depression, Psychotherapy, Breast milk, CEO, Research, Substance abuse, Metabolite, Journal of Psychoactive Drugs, Excoriation disorder, Infant, Journal, Mother, Pharmacokinetics, Medicine, Postpartum period, Crime, Birth control, Pharmaceutical industry, Ketamine
The research provides the first quantification of Ketamine and its major metabolites in human breast milk.
Key Points:
- The research provides the first quantification of Ketamine and its major metabolites in human breast milk.
- The Ketamine Research Foundation believes this study will help open the door for further explorations of ketamine in the treatment of emotional disorders of the postpartum period, said Dr. Philip Wolfson, CEO of The Ketamine Research Foundation and a widely recognized leader in the development of Ketamine Assisted Psychotherapy.
- The Ketamine Research Foundation is in the process of developing its protocol for postpartum depression and expects to launch it in the fall of 2022.
- The Ketamine Research Foundation stands at the apex of Ketamine research and ketamine psychotherapy.